| __timestamp | Ionis Pharmaceuticals, Inc. | Merck & Co., Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 20140000 | 11606000000 |
| Thursday, January 1, 2015 | 37173000 | 10313000000 |
| Friday, January 1, 2016 | 48616000 | 9762000000 |
| Sunday, January 1, 2017 | 108488000 | 9830000000 |
| Monday, January 1, 2018 | 244622000 | 10102000000 |
| Tuesday, January 1, 2019 | 287000000 | 10615000000 |
| Wednesday, January 1, 2020 | 354000000 | 8955000000 |
| Friday, January 1, 2021 | 186000000 | 9634000000 |
| Saturday, January 1, 2022 | 151000000 | 10042000000 |
| Sunday, January 1, 2023 | 232600000 | 10504000000 |
| Monday, January 1, 2024 | 267474000 |
Unleashing insights
In the ever-evolving pharmaceutical landscape, understanding the financial dynamics of industry leaders is crucial. Over the past decade, Merck & Co., Inc. and Ionis Pharmaceuticals, Inc. have showcased contrasting strategies in managing their Selling, General, and Administrative (SG&A) expenses. From 2014 to 2023, Merck's SG&A expenses have consistently dwarfed those of Ionis, averaging around $10 billion annually, a testament to its expansive global operations and marketing efforts. In contrast, Ionis, a smaller player, has seen its SG&A expenses grow from $20 million in 2014 to over $230 million in 2023, reflecting its strategic investments in growth and innovation. This 11-fold increase highlights Ionis's aggressive push to expand its market presence. As the pharmaceutical sector continues to innovate, these financial insights offer a glimpse into the strategic priorities of these two industry titans.
Johnson & Johnson and Merck & Co., Inc.: SG&A Spending Patterns Compared
Comparing SG&A Expenses: Merck & Co., Inc. vs AstraZeneca PLC Trends and Insights
Comparing SG&A Expenses: Merck & Co., Inc. vs Takeda Pharmaceutical Company Limited Trends and Insights
Breaking Down SG&A Expenses: Merck & Co., Inc. vs Verona Pharma plc
SG&A Efficiency Analysis: Comparing Merck & Co., Inc. and CymaBay Therapeutics, Inc.
Who Optimizes SG&A Costs Better? Merck & Co., Inc. or Viking Therapeutics, Inc.
Operational Costs Compared: SG&A Analysis of Merck & Co., Inc. and Celldex Therapeutics, Inc.
Comparing SG&A Expenses: Merck & Co., Inc. vs Xencor, Inc. Trends and Insights
Cost Management Insights: SG&A Expenses for Alnylam Pharmaceuticals, Inc. and Ionis Pharmaceuticals, Inc.
Ionis Pharmaceuticals, Inc. vs Apellis Pharmaceuticals, Inc.: SG&A Expense Trends
Cost Management Insights: SG&A Expenses for Ionis Pharmaceuticals, Inc. and Travere Therapeutics, Inc.
Selling, General, and Administrative Costs: Ionis Pharmaceuticals, Inc. vs Xencor, Inc.